Daptomycin Nonsusceptible Enterococci: An Emerging Challenge for Clinicians
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Daptomycin is the only antibiotic with in vitro bactericidal activity against vancomycin-resistant Enterococcus (VRE) that is approved by the Food and Drug Administration (FDA). Data on the potential emergence of daptomycin nonsusceptibility among enterococci remain limited. We systematically reviewed the published literature for reports of isolates of enterococci that were daptomycin nonsusceptible and assessed the clinical significance and outcome of therapy. Based on susceptibility breakpoints approved by the Clinical Laboratory Standards Institute (CLSI), daptomycin has in vitro activity against >90% of enterococcal isolates. Less than 2% of enterococcal isolates were daptomycin nonsusceptible, with minimum inhibitory concentrations (MICs) >4 μg/mL. The prevalence of nonsusceptibility of VRE isolates to daptomycin may be overestimated due to the spread of clonally related isolates in health care settings. Clinicians should be aware of the possibility of the emergence of daptomycin nonsusceptibility and should closely monitor daptomycin MICs of enterococci isolated during treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sampling the Antibiotic Resistome
D'Costa, V. M., McGrann, K. M., Hughes, D. W., & Wright, G. D. (2006) · Science · doi:10.1126/science.1120800 · Cited by 1,594 · cited 1×
“The mechanisms of nonsusceptibility to daptomycin have not been characterized, but the risk of gene transfer of daptomycin resistance determinants has been raised as a potential threat [36].”
BackgroundLaPlante, K. L., & Woodmansee, S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00134-09 · Cited by 110
Schutt, A. C., & Bohm, N. M. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m324 · Cited by 57
Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis
Hidron, A. I., Schuetz, A. N., Nolte, F. S., Gould, C. V., & Osborn, M. K. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn105 · Cited by 35
Infective endocarditis caused by daptomycin-resistant Enterococcus faecalis: A case report
Kanafani, Z. A., Federspiel, J. J., & Fowler, V. G. (2007) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540600786465 · Cited by 30 · cited 6×
“diffusion and dilution methods (Supplementary Table 3) [7, 9, 16, 22, 24, 27].”
BackgroundMethodInfluential
Cited by
Intrinsic and acquired resistance mechanisms in enterococcus
Hollenbeck, B. L., & Rice, L. B. (2012) · Virulence · doi:10.4161/viru.21282 · Cited by 795
“Jensen LB, Hammerum AM, Aarestrup FM. Linkage of vat(E) and erm(B) in streptogamin-resistant Enterococcus faecium isolates from Europe.”
BackgroundMethodInfluentialAhmed, M. O., & Baptiste, K. E. (2018) · Microbial Drug Resistance · doi:10.1089/mdr.2017.0147 · Cited by 438
The emerging problem of linezolid-resistant Staphylococcus
Gu, B., Kelesidis, T., Tsiodras, S., Hindler, J., & Humphries, R. M. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks354 · Cited by 332
Self-citationSakoulas, G., Bayer, A. S., Pogliano, J., Tsuji, B. T., Yang, S.-J., Mishra, N. N., Nizet, V., Yeaman, M. R., & Moise, P. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05551-11 · Cited by 176
“There have been a number of recent reports of isolation of daptomycin-resistant Staphylococcus aureus (17, 20–23, 27–29, 31, 39, 41) and enterococcus strains (24, 26) emerging during daptomycin treatment in patients with recalcitrant infections.”
BackgroundSakoulas, G., Rose, W., Nonejuie, P., Olson, J., Pogliano, J., Humphries, R., & Nizet, V. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02274-13 · Cited by 94
Self-citation
Metadata
- Authors
- Kelesidis, T., Humphries, R., Uslan, D. Z., & Pegues, D. A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-01-15
- Volume
- 52
- Issue
- 2
- Pages
- 228-234
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2075038827
- Cited by
- 146
- References
- 5
- FWCI
- 7.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.